Mirum Pharmaceuticals Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Mirum Pharmaceuticals stock.
View analyst ratings for Mirum Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Mirum Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Mirum Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Mirum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Mirum Pharmaceuticals.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) announced its quarterly earnings results on Thursday, May, 6th. The company reported ($1.68) earnings per share for the quarter, missing the consensus estimate of ($0.67) by $1.01.
View Mirum Pharmaceuticals' earnings history.

Mirum Pharmaceuticals' stock was trading at $11.73 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MIRM shares have increased by 50.0% and is now trading at $17.60.
View which stocks have been most impacted by COVID-19.

7 analysts have issued 12 month price objectives for Mirum Pharmaceuticals' shares. Their forecasts range from $30.00 to $52.00. On average, they expect Mirum Pharmaceuticals' share price to reach $40.17 in the next year. This suggests a possible upside of 128.2% from the stock's current price.
View analysts' price targets for Mirum Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Mirum Pharmaceuticals include Myovant Sciences (MYOV), Ligand Pharmaceuticals (LGND), Deciphera Pharmaceuticals (DCPH), Prothena (PRTA), Atea Pharmaceuticals (AVIR), Amarin (AMRN), Organogenesis (ORGO), Ironwood Pharmaceuticals (IRWD), Seres Therapeutics (MCRB), Centessa Pharmaceuticals (CNTA), Harmony Biosciences (HRMY), Amneal Pharmaceuticals (AMRX), Madrigal Pharmaceuticals (MDGL), Arcus Biosciences (RCUS) and Zymeworks (ZYME).
View all of MIRM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Pfizer (PFE), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Vaxart (VXRT), Advanced Micro Devices (AMD), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV) and Dynavax Technologies (DVAX).

(MIRM) raised $75 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.

Mirum Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIRM."

Mirum Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rock Springs Capital Management LP (4.93%), BlackRock Inc. (2.50%), Geode Capital Management LLC (0.57%), Northern Trust Corp (0.32%), Millennium Management LLC (0.27%) and Chartwell Investment Partners LLC (0.22%). Company insiders that own Mirum Pharmaceuticals stock include Christopher Peetz, Edwin Jonathan Tucker, Holdings A/S Novo, Ian Clements, James E Flynn, Laurent Fischer, Pamela Vig and Patrick J Heron.
View institutional ownership trends for Mirum Pharmaceuticals.

MIRM stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Nuveen Asset Management LLC, Chartwell Investment Partners LLC, Cubist Systematic Strategies LLC, Northern Trust Corp, and Bank of New York Mellon Corp.
View insider buying and selling activity for Mirum Pharmaceuticals or view top insider-selling stocks.

MIRM stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Panagora Asset Management Inc., Los Angeles Capital Management LLC, JPMorgan Chase & Co., GSA Capital Partners LLP, Pinnacle Advisory Group Inc., and Alps Advisors Inc.. Company insiders that have bought Mirum Pharmaceuticals stock in the last two years include Christopher Peetz, Edwin Jonathan Tucker, Holdings A/S Novo, Ian Clements, James E Flynn, Laurent Fischer, Pamela Vig, and Patrick J Heron.
View insider buying and selling activity for Mirum Pharmaceuticals or or view top insider-buying stocks.

Shares of MIRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MIRM stock can currently be purchased for approximately $17.60.

Mirum Pharmaceuticals has a market capitalization of $535.97 million. The company earns $-103,270,000.00 in net income (profit) each year or ($4.09) on an earnings per share basis.

Mirum Pharmaceuticals employs 85 workers across the globe.

The official website for Mirum Pharmaceuticals is mirumpharma.com.

Mirum Pharmaceuticals is headquartered at 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404.

Mirum Pharmaceuticals' mailing address is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. The company can be reached via phone at 650-667-4085 or via email at [email protected]